# Biogen Raises 2026 EPS Guidance Floor as Growth Portfolio Expands

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/42605
Published: 2026-10-28T13:20:20.000Z
Updated: 2026-10-28T13:20:20.000Z
Section: Business

> The Growth Portfolio generated $1.26 billion, up 49% year over year, while multiple sclerosis product revenue fell 13% to $919 million.

Biogen raised the lower end of its full-year 2026 non-GAAP diluted earnings-per-share guidance after its Growth Portfolio expanded 49% in the third quarter, even as multiple sclerosis product revenue declined.

The company now expects non-GAAP diluted EPS of $12.20 to $13.00 for 2026. It lifted the lower end from $12.00 and kept the upper end at $13.00.

Revenue reached $2.804 billion, up 11% year over year. The Growth Portfolio generated $1.26 billion and drove double-digit revenue growth. The quarter included the first full quarter of Apellis products.

Multiple sclerosis product revenue fell 13% to $919 million from $1.062 billion in the year-earlier quarter.